Investment
Remained an investor in Xeltis' additional EUR 20.5M raise toward FDA approval of its AXESS vascular access graft.
Xeltis
Every public signal F4 has attached to this firm, with sources and cross-entity links.
Xeltis
R1 Therapeutics
Greater Good Health
Miromatrix